Keywords: fda, panel, declines, vote, rx-to-otc, switch, merck

FDA panel declines to vote on Rx-to-OTC switch for Merck's Flexeril

Article | 23 July 1999

Print This

A US Food and Drug Administration advisory panel has not voted onwhether to recommend that Merck & Co's centrally-acting muscle relaxant ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in